Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
|Videos|October 8, 2021
MOSES 2.0 upgrade for HoLEP demonstrates cost savings in BPH
Author(s)Urology Times staff
“Even factoring in the increased number of emergency room visits, there was still an overall cost savings of $747 in favor of the Moses HoLEP. So, that was surprising to see,” says Matthew S. Lee, MD.
Advertisement
In this video Matthew S. Lee, MD,discusses the background and findings of the Urology Practice study, “A cost comparison of holmium laser enucleation of the prostate with and without Moses.” Lee is an endourology fellow at Northwestern University, Evanston, Illinois.
Advertisement
Related to this article
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.
Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.
Advertisement
Advertisement
Trending on Urology Times
1
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
Health Canada accepts vibegron submission for overactive bladder
5